Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
To the Editor: Alopecia areata (AA) is an autoimmune condition with limited treatment options, particularly in pediatric populations. There are no Food and Drug Administration –approved treatments for children with AA, and medications used for alopecia totalis (AT) and alopecia universalis (AU) lack large, controlled studies.1 The mainstays of treatment are topical or intralesional steroids and irritant therapy. Some families opt for systemic therapies, including oral c orticosteroids or off-label use of immunosuppressive drugs, such as methotrexate, cyclosporine A, mycophenolate mofetil, or azathioprine.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Elana Putterman, Leslie Castelo-Soccio Tags: Research letter Source Type: research
More News: Academies | Alopecia | Alopecia Areata | Alopecia Totalis | Alopecia Universalis | Children | Dermatology | Food and Drug Administration (FDA) | Methotrexate | Pediatrics | Restasis | Skin | Study